Patents by Inventor Joel S. Schuman

Joel S. Schuman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11406687
    Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: August 9, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
  • Publication number: 20220211632
    Abstract: A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least five days.
    Type: Application
    Filed: January 21, 2022
    Publication date: July 7, 2022
    Inventors: Morgan V. Fedorchak, Steven R. Little, Joel S. Schuman, Anthony Cugini
  • Publication number: 20220202705
    Abstract: A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is an antibody, a fusion protein, a chemokine, an interleukin, a growth factor, albumin, immunoglobulin, an interferon, a peptide, stem cell-conditioned media, plasma or serum.
    Type: Application
    Filed: January 18, 2022
    Publication date: June 30, 2022
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Morgan V. Fedorchak, Steven R. Little, Joel S. Schuman
  • Publication number: 20210369649
    Abstract: This document provided ocular delivery systems for treatment of cystinosis as well as methods for making such ocular delivery systems and methods for using such ocular delivery systems. For example, ocular delivery systems designed to include spray-dried, cysteamine-loaded microparticles suspended in a thermoresponsive gel are provided herein.
    Type: Application
    Filed: November 18, 2019
    Publication date: December 2, 2021
    Inventors: Morgan Virginia Fedorchak, Steven R. Little, Joel S. Schuman
  • Patent number: 10950353
    Abstract: A method for determining a disease state transition path includes receiving a patient data having functional data and/or structural data related to a patient. Based on the patient data, a first disease state of a plurality of non-overlapping disease states each associated with a predetermined range of functional and/or structural degeneration values may be identified. A second, non-adjacent disease state of the plurality of disease states may be identified based on the patient data. A most probable path between the first disease state and the second disease state may be determined using a two dimensional continuous-time hidden Markov model.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: March 16, 2021
    Assignees: Georgia Tech Research Corporation, University of Pittsburgh-of the Commonwealth System of Higher Education
    Inventors: Yu-Ying Liu, Hiroshi Ishikawa, James Rehg, Joel S. Schuman, Gadi Wollstein
  • Publication number: 20210015770
    Abstract: Methods for treating an ear condition in a subject, comprising topically administering to the ear of the subject in need thereof a composition comprising: (i) an anti-infective agent-loaded biodegradable polymer microspheres; and (ii) a thermoresponsive hydrogel.
    Type: Application
    Filed: December 10, 2018
    Publication date: January 21, 2021
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Morgan V. Fedorchak, Steven R. Little, Joel S. Schuman
  • Publication number: 20210000919
    Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 7, 2021
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
  • Patent number: 10561710
    Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: February 18, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
  • Publication number: 20190099365
    Abstract: A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is an antibody, a fusion protein, a chemokine, an interleukin, a growth factor, albumin, immunoglobulin, an interferon, a peptide, stem cell-conditioned media, plasma or serum.
    Type: Application
    Filed: March 21, 2017
    Publication date: April 4, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Morgan V. Fedorchak, Steven R. Little, Joel S. Schuman
  • Publication number: 20180333460
    Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.
    Type: Application
    Filed: January 9, 2018
    Publication date: November 22, 2018
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
  • Publication number: 20180280478
    Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.
    Type: Application
    Filed: December 19, 2017
    Publication date: October 4, 2018
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
  • Patent number: 9980641
    Abstract: The innovation provides for a system and method available to image and visualize the palisades of Vogt via a non-contact process, analyze the image volumes acquired, evaluate the status of the palisades of Vogt from the data represented therein, and display the data in real-time or as a part of a medical record for ongoing consideration and evaluation.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: May 29, 2018
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Kira L. Lathrop, Joel S. Schuman, Lawrence E. Kagemann
  • Patent number: 9895419
    Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: February 20, 2018
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
  • Patent number: 9872889
    Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: January 23, 2018
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
  • Publication number: 20170000852
    Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.
    Type: Application
    Filed: January 20, 2015
    Publication date: January 5, 2017
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
  • Publication number: 20160361387
    Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.
    Type: Application
    Filed: August 24, 2016
    Publication date: December 15, 2016
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
  • Patent number: 9514513
    Abstract: Advances in optical coherence tomography (OCT) have prompted a transition from time domain OCT, providing 2D OCT images, to spectral domain OCT, which has a 3D imaging capability. Yet conventional technology offers little toward the goal of inter-device compatibility between extant 2D OCT images and newer 3D OCT images for the same or comparable subjects, as in the context of ongoing monitoring the quantitative status of a patient's eyes. The inventive methodology is particularly useful to identify the scan location of tissue in a 2D OCT image within the 3D OCT volumetric data, thereby allowing clinicians to image a patient via 3D OCT, based on available 2D OCT images, with minimal inter-device variation.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: December 6, 2016
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Jong S. Kim, Hiroshi Ishikawa, Joel S. Schuman, Gadi Wollstein
  • Patent number: 9452200
    Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: September 27, 2016
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
  • Publication number: 20160232324
    Abstract: A method for determining a disease state transition path includes receiving a patient data having functional data and/or structural data related to a patient. Based on the patient data, a first disease state of a plurality of non-overlapping disease states each associated with a predetermined range of functional and/or structural degeneration values may be identified. A second, non-adjacent disease state of the plurality of disease states may be identified based on the patient data. A most probable path between the first disease state and the second disease state may be determined using a two dimensional continuous-time hidden Markov model.
    Type: Application
    Filed: September 19, 2014
    Publication date: August 11, 2016
    Inventors: Yu-Ying Liu, Ishikawa Hiroshi, James Rehg, Joel S. Schuman, Gadi Wollstein
  • Publication number: 20160022779
    Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.
    Type: Application
    Filed: October 8, 2015
    Publication date: January 28, 2016
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman